<DOC>
	<DOCNO>NCT00366106</DOCNO>
	<brief_summary>The current study conduct evaluate possibility different schedule bortezomib , doxorubicin HCl liposome , dexamethasone might decrease incidence peripheral neuropathy yet maintain similar efficacy allow maintenance bortezomib dose long period .</brief_summary>
	<brief_title>Alternative Schedule Velcade/Dexamethasone Plus Doxil Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient least 18 year age . Patient confirm diagnosis relapsed/refractory multiple myeloma measurable disease serum urine . Measurable disease define monoclonal protein ≥ 1g/dl serum protein electrophoresis ( SPEP ) &gt; 200 mg urine M protein/ 24 hour Patient receive least 1 prior treatment regimen . ( Prior treatment bortezomib allow . ) Patient ECOG ≤ 2 Patient provide voluntary write informed consent performance studyrelates procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Patients receive prior high dose chemotherapy stem cell support eligible study . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . Patient platelet count &lt; 50 , 000 cells/mm³ , within 14 day enrollment . Patient absolute neutrophil count ( ANC ) ≤ 750/mm³ within 14 day enrollment . Patient calculate measured creatinine clearance &lt; 20 mL/min within 14 day enrollment and/or serum creatinine ≥ 2.5 mg/dl . Patient hemoglobin &lt; 7.5 g/dl . Patient ≥ Grade 2 peripheral neuropathy within 14 day enrollment . Myocardial infarction within 6 month prior enrollment ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , electrocardiogram ( ECG ) abnormality screen document investigator medically relevant . Patient receive total cumulative dosage anthracyclines exceed 550 mg/m2 . Patient hypersensitivity boron mannitol . Patient history hypersensitivity reaction conventional formulation doxorubicin HCl component DOXIL . Patient clinically significant coexist illness unrelated myeloma . Patient uncontrolled diabetes . Patient plasma cell leukemia . Patient serum bilirubin &gt; 1.5 x upper normal limit , alanine aminotransaminase ( ALT ) , aspartate aminotransferase ( AST ) &gt; 2.5 x upper normal limit ( ULN ) , alkaline phosphatase &gt; 2.5 x ULN . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( BhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Patient receive investigational drug within 14 day enrollment . Patient serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
</DOC>